more

McKesson (MCK)

(Real Time Quote from BATS)

$589.88 USD

+4.14 (0.71%)

Updated Jul 24, 2024 03:55 PM ET

After-Market: $590.28 +0.40 (0.07%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research Published on January 27,2023

McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research Published on January 27,2023

AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

What's in the Cards for Illumina (ILMN) in Q4 Earnings?

by Zacks Equity Research Published on January 26,2023

Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.

CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on January 26,2023

CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q4.

Cardinal Health (CAH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research Published on January 26,2023

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Value Investors Buy Cardinal Health (CAH) Stock?

by Zacks Equity Research Published on January 26,2023

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research Published on January 26,2023

Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.